Matches in Wikidata for { <http://www.wikidata.org/entity/Q64806594> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- Q64806594 description "clinical trial" @default.
- Q64806594 description "ensayu clínicu" @default.
- Q64806594 description "klinisch onderzoek" @default.
- Q64806594 description "клінічне випробування" @default.
- Q64806594 name "A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis" @default.
- Q64806594 type Item @default.
- Q64806594 label "A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis" @default.
- Q64806594 prefLabel "A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis" @default.
- Q64806594 P1050 Q64806594-F0704152-2E1D-42C2-BC0D-DDAC0490B8B8 @default.
- Q64806594 P1132 Q64806594-3BDC8C60-04B4-439E-A89B-08AADBD1A32D @default.
- Q64806594 P1476 Q64806594-F1A3CB24-0CE6-4CC8-A855-5654864DE5DB @default.
- Q64806594 P17 Q64806594-081DDB61-3560-4C25-A7F3-842DC984B9E7 @default.
- Q64806594 P17 Q64806594-14D6A7D3-BF13-4625-A100-0EA45D645C08 @default.
- Q64806594 P17 Q64806594-25A38467-EE05-4A22-82F3-5442D3F7A8A1 @default.
- Q64806594 P17 Q64806594-3E5A0A6C-D9E2-40BB-AACD-F88F150926A5 @default.
- Q64806594 P17 Q64806594-6B221281-5384-4D79-A89E-4659166E8A35 @default.
- Q64806594 P17 Q64806594-90CC2B7E-1185-48A6-9C20-38C55E02DA7A @default.
- Q64806594 P17 Q64806594-AF80D09F-091B-4CFA-B63E-0F448FE81B13 @default.
- Q64806594 P17 Q64806594-C0E5FF13-AEAA-4A91-8BDB-03F9DA77E052 @default.
- Q64806594 P17 Q64806594-DC492527-F32C-4284-A23E-8BC3897B6C83 @default.
- Q64806594 P17 Q64806594-EEB5958D-886B-4CD2-8132-7B37687D7A0C @default.
- Q64806594 P1813 Q64806594-28795E85-9976-42AB-B3FC-B3C41E974500 @default.
- Q64806594 P2899 Q64806594-FFF3B943-6531-4A42-9B80-EB7A6E4E3BD1 @default.
- Q64806594 P3098 Q64806594-3B46A013-C02D-430B-A199-ECB83C419B6C @default.
- Q64806594 P31 Q64806594-BD38AA97-B5DC-4657-A2F1-546AE3A3C7DE @default.
- Q64806594 P580 Q64806594-6C16A650-8B9E-4460-87FE-67C122157EB8 @default.
- Q64806594 P582 Q64806594-B5EB1235-98B7-440B-8C38-A36B459EAD5C @default.
- Q64806594 P6099 Q64806594-A692D064-DA25-4784-8480-624771BD0D02 @default.
- Q64806594 P8363 Q64806594-05FF7A1E-2ECC-432A-BCFC-51BA55C2548F @default.
- Q64806594 P1050 Q179945 @default.
- Q64806594 P1132 "+570" @default.
- Q64806594 P1476 "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis" @default.
- Q64806594 P17 Q145 @default.
- Q64806594 P17 Q16 @default.
- Q64806594 P17 Q17 @default.
- Q64806594 P17 Q183 @default.
- Q64806594 P17 Q28 @default.
- Q64806594 P17 Q30 @default.
- Q64806594 P17 Q31 @default.
- Q64806594 P17 Q36 @default.
- Q64806594 P17 Q38 @default.
- Q64806594 P17 Q408 @default.
- Q64806594 P1813 "BE VIVID" @default.
- Q64806594 P2899 "+18" @default.
- Q64806594 P3098 "NCT03370133" @default.
- Q64806594 P31 Q30612 @default.
- Q64806594 P580 "2017-12-06T00:00:00Z" @default.
- Q64806594 P582 "2019-01-08T00:00:00Z" @default.
- Q64806594 P6099 Q42824827 @default.
- Q64806594 P8363 Q78089383 @default.